Trinity Biotech Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Trinity Biotech kazanç ve gelirinin sırasıyla yıllık 33.2% ve 11.8% oranında artması tahmin edilirken, EPS'nin yıllık 55.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

33.2%

Kazanç büyüme oranı

55.6%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.1%
Gelir büyüme oranı	11.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:TRIB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	78	-8	3	6	1
12/31/2025	69	-15	-11	-8	1
12/31/2024	62	-20	-10	-9	1
9/30/2024	59	-20	-16	-7	N/A
6/30/2024	59	-22	-14	-8	N/A
3/31/2024	57	-34	-15	-12	N/A
12/31/2023	57	-37	-14	-12	N/A
9/30/2023	71	-39	-13	-10	N/A
6/30/2023	54	-46	-8	-5	N/A
3/31/2023	74	-34	-7	-2	N/A
12/31/2022	63	-44	-7	-1	N/A
9/30/2022	76	-32	-6	2	N/A
6/30/2022	79	-22	-5	3	N/A
3/31/2022	86	-13	-2	6	N/A
12/31/2021	81	-2	5	13	N/A
9/30/2021	106	-8	11	20	N/A
6/30/2021	116	-2	18	27	N/A
3/31/2021	106	-2	19	29	N/A
12/31/2020	102	-6	14	24	N/A
9/30/2020	91	-20	-1	7	N/A
6/30/2020	83	-27	-6	5	N/A
3/31/2020	90	-31	-2	10	N/A
12/31/2019	90	-29	-6	5	N/A
9/30/2019	94	-30	-4	11	N/A
6/30/2019	93	-29	-7	9	N/A
3/31/2019	95	-23	-7	9	N/A
12/31/2018	97	-23	-10	7	N/A
9/30/2018	97	-39	-10	7	N/A
6/30/2018	99	-40	N/A	8	N/A
3/31/2018	99	-40	N/A	10	N/A
12/31/2017	99	-39	N/A	9	N/A
9/30/2017	98	-36	N/A	8	N/A
6/30/2017	99	-37	N/A	10	N/A
3/31/2017	100	-36	N/A	8	N/A
12/31/2016	100	-39	N/A	10	N/A
9/30/2016	101	3	N/A	17	N/A
6/30/2016	101	16	N/A	14	N/A
3/31/2016	98	16	N/A	13	N/A
12/31/2015	100	22	N/A	13	N/A
9/30/2015	101	23	N/A	15	N/A
6/30/2015	103	15	N/A	17	N/A
3/31/2015	105	17	N/A	16	N/A
12/31/2014	105	15	N/A	16	N/A
9/30/2014	103	18	N/A	8	N/A
6/30/2014	100	10	N/A	6	N/A
3/31/2014	95	10	N/A	8	N/A
12/31/2013	91	10	N/A	9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TRIB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: TRIB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: TRIB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: TRIB şirketinin gelirinin (yıllık 11.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: TRIB şirketinin gelirinin (yıllık 11.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TRIB 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Trinity Biotech Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Trinity Biotech plc Provides Preliminary Revenue Guidance for the Second Quarter of 2024

Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Consensus EPS estimates fall by 47%

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Consensus revenue estimates fall by 17%

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Trinity Biotech plc to Report Q3, 2024 Results on Nov 15, 2024

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Trinity Biotech plc (NasdaqGS:TRIB) acquired EpiCapture Limited for $3.6 million.

Trinity Biotech plc Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Second quarter 2024 earnings: EPS misses analyst expectations

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Trinity Biotech plc (NasdaqGS:TRIB) acquired Metabolomic Diagnostics Ltd. for an enterprise value of $1.3 million.

Trinity Biotech plc to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Trinity Biotech plc Provides Update on the Continued Development of its Glucose Biosensor Technology

Trinity Biotech plc, Annual General Meeting, Sep 30, 2024

Trinity Biotech plc Appoints Global Life Sciences Leader Adrian Donohue as Chief Commercial Officer

Trinity Biotech Appoints David Ouston as Biosensor Marketing Director

Second quarter 2024 earnings: Revenues in line with analyst expectations

Trinity Biotech plc to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Trinity Biotech Obtains an Extension to Demonstrate Compliance with Nasdaq Listing Requirements

Trinity Biotech plc Provides Preliminary Revenue Guidance for the Second Quarter of 2024

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc Announces Chief Financial Officer Changes

Trinity Biotech plc to Begin European Pre-Pivotal Trial to Optimize Its Cgm Sensor

New minor risk - Share price stability

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Trinity Biotech plc Launches Its Continuous Glucose Monitoring Microsite to Showcase Its Innovative & Differentiated Technology

Trinity Biotech plc Receives A Staff Determination Letter Regarding MVPHS Requirement by May 20, 2024

Trinity Biotech plc to Report Q1, 2024 Results on May 23, 2024

Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024

Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Full year 2023 earnings released: US$4.82 loss per share (vs US$6.46 loss in FY 2022)

Full year 2023 earnings released

Trinity Biotech plc to Report Q4, 2023 Results on Apr 04, 2024

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

New minor risk - Shareholder dilution

New major risk - Share price stability

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released

Trinity Biotech to Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

Trinity Biotech plc Announces CEO Changes

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Trinity Biotech plc Appoints Andrew Omidvar as Director

Consensus EPS estimates fall by 47%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Trinity Biotech plc to Report Q2, 2023 Results on Oct 03, 2023

Now 20% undervalued after recent price drop

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Trinity Biotech plc, Annual General Meeting, Sep 29, 2023

Trinity Biotech plc Announces Receives 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Consensus revenue estimates fall by 17%

New minor risk - Profitability

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Trinity Biotech plc to Report Q1, 2023 Results on Jul 06, 2023

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Consensus revenue estimates fall by 11%

Full year 2022 earnings: Revenues in line with analyst expectations

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 54%

Trinity Biotech plc to Report Q3, 2022 Results on Dec 15, 2022

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.037 loss in 2Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2022

Trinity Biotech plc to Report Q2, 2022 Results on Nov 03, 2022